SCHEMBL18171689

SCHEMBL18171689

COc1cc(-c2cccc(N)c2)c(-n2ccnc2)cc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.50
CYP11B1 P15538 1/20 0.50
CYP11B2 P19099 1/20 0.50
CYP1A2 P05177 5/20 0.45
CYP3A4 P08684 5/20 0.45
CYP2D6 P10635 5/20 0.45
CYP2C19 P33261 5/20 0.45
LMNA P02545 4/20 0.45
TDP1 Q9NUW8 4/20 0.45
HSD17B10 Q99714 3/20 0.45
KDM4E B2RXH2 3/20 0.45
MAPT P10636 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
CYP2C9 P11712 1/20 0.45
TP53 P04637 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
FYN P06241 2/20 0.42
CGAS Q8N884 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28133820 0.81 LMNA (0.46) CYP19A1CYP11B1CYP11B2CYP1A2CYP3A4
SCHEMBL18171690 0.79 PDE10A (0.47) CYP19A1CYP11B1CYP11B2CYP1A2CYP3A4
SCHEMBL11702866 0.76 CYP11B1 (0.60) CYP19A1CYP11B1CYP11B2CYP1A2CYP3A4
SCHEMBL1037506 0.76 CYP11B1 (0.60) CYP19A1CYP11B1CYP11B2CYP1A2CYP3A4
SCHEMBL28090553 0.73 CYP19A1 (0.51) CYP19A1CYP11B1CYP11B2CYP1A2CYP3A4
SCHEMBL27754717 0.72 MEN1 (0.49) CYP19A1CYP11B1CYP11B2CYP1A2CYP3A4
SCHEMBL3513470 0.71 BRD4 (0.52) CYP19A1CYP11B1CYP11B2CYP1A2CYP3A4
SCHEMBL28637569 0.71 JAK2 (0.49) CYP1A2LMNAMAPTALDH1A1FYN
SCHEMBL6756834 0.70 FYN (0.52) CYP19A1CYP11B1CYP11B2CYP1A2CYP3A4
SCHEMBL31149024 0.69 CYP19A1 (0.67) CYP19A1CYP11B1CYP11B2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3285808-A1 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH SYK INHIBITORS Gilead Sciences, Inc. (US) 2018-02-28 EP disclosed
WO-2016172117-A1 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH SYK INHIBITORS GILEAD SCIENCES, INC. (US) 2016-10-27 WO disclosed